Wall Street Zen Upgrades Synaptogenix (NASDAQ:TAOX) to “Hold”

Synaptogenix (NASDAQ:TAOX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Synaptogenix Stock Performance

NASDAQ:TAOX opened at $4.43 on Friday. The stock has a 50-day simple moving average of $3.78 and a two-hundred day simple moving average of $4.38. The firm has a market capitalization of $33.14 million, a PE ratio of -1.15 and a beta of 1.49. Synaptogenix has a 52-week low of $3.07 and a 52-week high of $10.00.

Synaptogenix (NASDAQ:TAOX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.83) EPS for the quarter. Synaptogenix had a negative return on equity of 128.51% and a negative net margin of 2,153.97%.The company had revenue of $0.09 million during the quarter.

About Synaptogenix

Synaptogenix, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc and adopted the Synaptogenix name as part of a corporate rebranding.